Vía trasera de la síntesis de testosterona (backdoor pathway)

Huggins, 1941, The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate, Cancer Res, 1, 293 Morgentaler, 2006, Testosterone and prostate cancer: An historical perspective on a modern myth, Eur Urol, 50, 935, 10.1016/j.eururo.2006.06.034 Khera, 2014, A new era of testosterone and prostate cancer: from physiology to clinical implications, Eur Urol, 65, 115, 10.1016/j.eururo.2013.08.015 Isbarn, 2009, Testosterone and prostate cancer: Revisiting old paradigms, Eur Urol, 56, 48, 10.1016/j.eururo.2009.03.088 Isaacs, 1999, Molecular genetics of prostate cancer, 545 Small, 1999, The androgen receptor and the physiology and endocrinology of the prostate, 565 Uribe, 2005, Cáncer de próstata. ¿Por qué se produce el cáncer de próstata? Aproximación a un modelo genético y molecular, Urol Colomb, 14, 25 Roddam, 2008, Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies, J Natl Cancer Inst, 100, 170, 10.1093/jnci/djm323 Krieger, 1998, The ‘best’ of cholesterols, the ‘worst’ of cholesterols: A tale of two receptors, Proc Natl Acad Sci U S A, 95, 4077, 10.1073/pnas.95.8.4077 Payne, 2004, Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones, Endocr Rev, 25, 947, 10.1210/er.2003-0030 2013 Ma, 2009, Atlas of dihydrotestosterone actions on the transcriptome of prostate in vivo, Prostate, 69, 293, 10.1002/pros.20883 Fluck, 2003, The 17,20-lyase activity of cytochrome P450c17 from human fetal testis favors the delta-5 steroidogenic pathway, J Clin Endocrinol Metab, 88, 3762, 10.1210/jc.2003-030143 Kamrath, 2012, Increased activation of the alternative ‘backdoor’ pathway in patients with 21-hydroxylase deficiency: Evidence from urinary steroid hormone analysis, J Clin Endocrinol Metab., 97, E367, 10.1210/jc.2011-1997 Auchus, 2004, The backdoor pathway to dihydrotestosterone, Trends Endocrinol Metab, 15, 432, 10.1016/S1043-2760(04)00214-0 Gardiner, 2009, Testosterone therapy in castrate-resistant prostate cancer: A possible new approach, Eur Urol., 56, 245, 10.1016/j.eururo.2009.04.030 Locke, 2008, Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer, Cancer Res, 68, 6407, 10.1158/0008-5472.CAN-07-5997 Cheng, 2010, The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction, Cancer Biol Ther., 9, 1033, 10.4161/cbt.9.12.11876 Montgomery, 2008, Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth, Cancer Res, 68, 4447, 10.1158/0008-5472.CAN-08-0249 Dillard, 2008, Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol, Mol Cell Endocrinol, 295, 115, 10.1016/j.mce.2008.08.013 Page, 2006, Persistent intraprostatic androgen concentrations after medical castration in healthy men, J Clin Endocrinol Metab, 91, 3850, 10.1210/jc.2006-0968 Chopra, 2015, Management of castration-resistant (advanced) prostate cancer (CRPC): Rationale, progress and future directions, Aust Fam Physician., 44, 302 Xu, 2015, Androgen receptor splice variants dimerize to transactivate target genes, Cancer Res., 75, 3663, 10.1158/0008-5472.CAN-15-0381 Boegemann, 2015, Present, emerging and possible future biomarkers in castration resistant prostate cancer (CRPC), Curr Cancer Drug Targets., 15, 243, 10.2174/1568009615666150204145803 Heidenreich, 2013, Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know, Eur Urol., 64, 260, 10.1016/j.eururo.2013.05.021 Muller, 2012, Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial, Eur Urol, 62, 757, 10.1016/j.eururo.2012.05.025 Pham, 2014, Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro, J Steroid Biochem Mol Biol., 144, 436, 10.1016/j.jsbmb.2014.09.004 Antonarakis, 2009, Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?, Nat Clin Pract Oncol, 6, 12, 10.1038/ncponc1262 Grist, 2015, The development of abiraterone acetate for castration-resistant prostate cancer, Urol Oncol., 33, 289, 10.1016/j.urolonc.2015.03.021 Bambury, 2015, Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide, Urol Oncol., 10.1016/j.urolonc.2015.05.025 Rodriguez-Vida, 2015, Enzalutamide for the treatment of metastatic castration-resistant prostate cancer, Drug Des Devel Ther, 9, 3325, 10.2147/DDDT.S69433 Jentzmik, 2015, Androgen receptor aberrations in the era of abiraterone and enzalutamide, World J Urol